09:14 AM EDT, 06/06/2024 (MT Newswires) -- Health care stocks were steady premarket Thursday with the iShares Biotechnology ETF (IBB) and Health Care Select Sector SPDR Fund ( XLV ) recently inactive.
Moderna ( MRNA ) was up nearly 4% after saying the US Food and Drug Administration has selected its experimental therapy, mRNA-3705, to treat methylmalonic acidemia, a rare genetic disorder, for a pilot program aimed at supporting clinical trials to advance rare disease therapeutics.
Annexon ( ANNX ) declined nearly 8% after it priced an underwritten public offering of about 13 million common shares at $6.25 per share, and pre-funded warrants to buy 7 million shares at $6.249 per share, for expected gross proceeds of $125 million.
Halozyme Therapeutics ( HALO ) was up past 5%, saying it raised its 2024 guidance Thursday after receiving a European patent for its Enhanze drug delivery platform a day earlier.